Complete report $19,700.  DataPack (test volumes, sales forecasts, supplier shares) $12,800.

This new report is a five-country strategic analysis of major business opportunities emerging in the clinical chemistry and immunodiagnostic markets during the next five years. The report explores future trends in major European countries (France, Germany, Italy, Spain, UK); provides estimates of the specimen, test and sales volumes, as well as major suppliers’ sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years.

The report provides five-year volume and sales forecasts for over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in hospitals, commercial laboratories, physician offices, and ambulatory care centers, including controls, calibrators and consumables.

Rationale

The clinical chemistry and immunodiagnostic markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition.  Some segments, like routine chemistry, are already resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.

Worldwide Market Overview

- Estimates of facilities performing clinical chemistry 
and immunodiagnostic tests by country.

- Test volume and sales projections by country.

Strategic Recommendations

- New product development opportunities
with significant market appeal.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

Competitive Assessments

- Strategic assessments of major suppliers and
emerging market entrants, including their sales, product
portfolios, marketing tactics, collaborative
arrangements and new products in R&D. 

- The companies analyzed in the report include
Abbott, AdnaGen, Agilent, Alere, Beckman Coulter/Danaher, Biomedical Diagnostics, bioMerieux, Bio-Rad, DiaSorin, Eiken, Fujirebio, Grifols IL, Kyowa Medex, Matritech/Alere, Ortho-Clinical Diagnostics, Roche, Siemens, Sysmex, Thermo Fisher, Tosoh, Wako, Wallac/PE.

Tests Analyzed in the Report:

Routine Clinical Chemistry

Albumin, Alkaline Phosphatase, ALT/SGPT, Ammonia, Amylase, AST/SGOT, Bilirubin, Bilirubin Direct, Bilirubin Total, BUN (Blood Urea Nitrogen), Calcium, Cardio CRP, Carbon Dioxide/Bicarbonate, Chloride, Cholesterol, Creatine Kinase (CK), CK-MB, Creatinine, GGT, Cystatin C, Ferritin, Fructosamine, Glucose, HDL Cholesterol, Homocysteine, Insulin, Iron, Iron Total Binding Capacity, Iron Unsaturated Binding Capacity, LDH, LDL Cholesterol, LDL Cholesterol Direct, Lipase, Lipoprotein a, Magnesium, Microalbumin, Phosphorus, Potassium, Sodium, Total Protein, Triglycerides, Troponin, Uric Acid.

Therapeutic Drug Monitoring (TDM)

Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam,
Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Sirolimus,
Tacrolimus, Theophylline, Tobramycin, Topirimate, Valproic Acid, Vancomycin.

Endocrine Function

Cortisol, Estradiol, FSH, HCG, Gastrin, LH, Progesterone, PTH/IO PTH,
Prolactin, T3, T3 Uptake,  Free T3, T4, Free T4, TBG, Testosterone,
Thyroglobulin Ab,  TPO Ab, TSH.

Tumor Markers and Special Chemistry

AFP, CA 15-3/27-29, CA 19-9, CEA, Ferritin, Follate (Folic Acid),
Glycosylated Hemoglobin, HCG, 25-Hydroxy Vitamin D2 and D3, Occult Blood,
PAP, PSA, Thyroglobulin, Vitamin B-12.

Immunoproteins

C3, C4, Free Light Chains, Haptoglobin, IgA, IgE Specific, IgE Total, IgG, IgM,
Immunofixation, Prealbumin, Protein Electrophoresis.

Drugs of Abuse

Amphetamines, Barbiturates, Benzodiazepines, Cannabinoids/Marijuana, Cocaine,
LSD, Methadone, Methaqualone, Opiates, Phencyclidine (PCP),
Propoxyphene, Tricyclic Antidepressants.

Geographic Coverage

- France
- Germany
- Italy
- Spain
- UK

Market Segmentation Analysis

- Comprehensive review of the market
dynamics, trends, structure, size, growth,
and key suppliers, by country.

- Test volume and sales forecasts for over 100 clinical chemistry,
TDM, endocrine, cancer, immunoprotein and abused drug assays,
by country and market segment:
    
     ° Hospitals
     ° Commercial/Private Laboratories
     ° Physician Offices/Group Practices
     ° Ambulatory Care Centers

Current and Emerging Products

- Analysis of current and emerging clinical chemistry
and immunodiagnostic tests.

- Review of current instrumentation technologies, and feature comparison
of high-, medium-, and low-volume/POC analyzers.

Technology Review

- Assessment of current and emerging
technologies, and their potential  market applications.

- Comprehensive lists of companies developing
or marketing new technologies and products by test.

Contains 900 pages and 335 tables